EGFR and head and neck squamous cell carcinoma: In line with these data, such EGFR-targeted agents as the small molecule tyrosine kinase inhibitors (i.e. gefitinib and erlotinib) and the monoclonal antibodies (i.e. cetuximab and panitumumab) provide clinical benefit to HNSCC patients [10], [11], [12], [13].